Medtronic plc
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|
| Revenue | $29.95B | $29.71B | $28.83B | $20.26B | $17.01B | $16.59B |
| Cardiovascular | $11.35B | — | $10.20B | — | — | — |
| Medical Surgical | $8.72B | — | $9.57B | — | — | — |
| Neuroscience | $7.74B | — | $7.22B | — | — | — |
| Diabetes | $2.14B | — | $1.85B | — | — | — |
| Cost of Revenue | $9.07B | $9.29B | $9.14B | $6.31B | $4.33B | $4.13B |
| Gross Profit | $20.90B | $20.42B | $19.69B | $13.95B | $12.67B | $12.46B |
| Gross Margin | 69.8% | 68.7% | 68.3% | 68.9% | 74.5% | 75.1% |
| Operating Expenses | ||||||
| Research & Development | — | — | — | — | — | — |
| SG&A Expense | $10.24B | $10.02B | $9.47B | $6.90B | $5.85B | $5.70B |
| Operating Income | $6.64B | $5.38B | $5.36B | $3.77B | $3.81B | $4.40B |
| Operating Margin | 22.2% | 18.1% | 18.6% | 18.6% | 22.4% | 26.5% |
| Interest Expense | $1.15B | $1.09B | $1.39B | $666.0M | $379.0M | $388.0M |
| Pretax Income | $5.68B | $4.60B | $4.34B | $3.49B | $3.71B | $4.25B |
| Income Tax Expense | $2.58B | $578.0M | $798.0M | $811.0M | $640.0M | $784.0M |
| Net Income | $3.10B | $4.03B | $3.54B | $2.68B | $3.07B | $3.47B |
| Net Margin | 10.4% | 13.6% | 12.3% | 13.2% | 18.0% | 20.9% |
| EPS (Basic) | $2.29 | $2.92 | $2.51 | $2.44 | $3.06 | $3.40 |
| EPS (Diluted) | $2.27 | $2.89 | $2.48 | $2.41 | $3.02 | $3.37 |
| Shares Outstanding (Basic) | 1.36B | 1.38B | 1.41B | 1.10B | 1.00B | 1.02B |
| Shares Outstanding (Diluted) | 1.37B | 1.39B | 1.43B | 1.11B | 1.01B | 1.03B |
| Dividends Per Share | $1.84 | $1.72 | $1.52 | $1.22 | $1.12 | $1.04 |